Last mentioned: Mar 10, 2026
Clinical Milestones
Anticipated updates on Phase 1/2 trial progress for MT-125 in GBM.
BioFlorida Showcase
Presentation in the Cornerstone Session: Innovation at BioFlorida.
Investival Showcase
Participation in the South Florida - The Rising Life Science Hub event.
Conference Announcement
Invited to present at two major South Florida life sciences events.
Partnering Circuit
Presented at BioCom California Global Life Science Partnering Conference.
Myosin Therapeutics is set to present its first-in-class NMIIA/IIB inhibitor, MT-125, at two major South Florida life sciences conferences this March. The company's unique approach targets the physical mechanics of glioblastoma cells, offering a potential solution to traditional drug resistance.
Mayo Clinic has launched a new patient information office in the Cayman Islands to streamline access to its specialized medical services for Caribbean residents. The facility will serve as a dedicated hub for coordinating appointments, travel logistics, and clinical communication between local physicians and Mayo’s U.S.-based specialists.
Merck and Mayo Clinic have launched a strategic R&D collaboration to integrate artificial intelligence into drug discovery and precision medicine. The partnership combines Mayo Clinic's vast clinical data with Merck's therapeutic expertise to identify novel drug targets and personalize patient care.
Merck and Mayo Clinic have entered a multi-year research and development collaboration to leverage artificial intelligence for drug discovery and personalized patient care. The partnership integrates Merck's pharmaceutical expertise with Mayo Clinic's clinical data and AI capabilities to accelerate the development of targeted therapies.